Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$3.15M$3.15M−22.4% vs Q2 2022 Net Income-$24.05M-$24.05MN/M vs Q2 2022 EPS Diluted-$0.51-$0.51N/M vs Q2 2022 Operating Income-$24,610,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$22,442,000N/M Margins · derivedOperating margin-781.8%−405.9 pt vs Q2 2022
Net margin-763.8%−391.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end